Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.48
+0.30 (1.42%)
Dec 31, 2025, 4:00 PM EST - Market closed
Immunome Revenue
Immunome had revenue of $9.68M in the twelve months ending September 30, 2025, down -4.44% year-over-year. In the year 2024, Immunome had annual revenue of $9.04M, down -35.50%.
Revenue (ttm)
$9.68M
Revenue Growth
-4.44%
P/S Ratio
176.05
Revenue / Employee
$82,025
Employees
118
Market Cap
1.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMNM News
- 15 days ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 16 days ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire
- 17 days ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire
- 17 days ago - Immunome's experimental drug meets main goal in late-stage study - Reuters
- 17 days ago - Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
- 18 days ago - Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
- 4 weeks ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome to Present at Upcoming Investor Conferences - Business Wire